22nd Century Group Stock Scheduled to Reverse Split on Tuesday, April 2nd (NASDAQ:XXII)

22nd Century Group, Inc. (NASDAQ:XXII) shares are scheduled to reverse split before the market opens on Tuesday, April 2nd. The 1-16 reverse split was announced on Tuesday, April 2nd. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, April 2nd.

22nd Century Group Stock Performance

Shares of XXII stock traded down $0.01 during trading hours on Friday, reaching $0.12. The company had a trading volume of 3,495,353 shares, compared to its average volume of 1,216,440. The business has a fifty day moving average price of $0.15 and a 200-day moving average price of $0.36. 22nd Century Group has a one year low of $0.10 and a one year high of $12.00. The firm has a market cap of $3.71 million, a PE ratio of -0.01 and a beta of 1.54. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.62 and a current ratio of 1.02.

Institutional Trading of 22nd Century Group

A number of large investors have recently made changes to their positions in the stock. Mercer Global Advisors Inc. ADV bought a new stake in shares of 22nd Century Group in the third quarter worth approximately $74,000. HighTower Advisors LLC bought a new stake in 22nd Century Group during the third quarter valued at approximately $77,000. Osaic Holdings Inc. grew its position in 22nd Century Group by 13.7% during the second quarter. Osaic Holdings Inc. now owns 241,087 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 29,047 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in 22nd Century Group during the second quarter valued at approximately $133,000. Finally, Ergoteles LLC bought a new stake in 22nd Century Group during the second quarter valued at approximately $62,000. 18.06% of the stock is currently owned by institutional investors.

22nd Century Group Company Profile

22nd Century Group, Inc, an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies.